Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from ...

Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The partnership splits the rights to Stoke’s epilepsy antisense oligonucleotide, with up to $385 million in potential ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a ...

Biogen ( NASDAQ: BIIB) and Stoke Therapeutics ( NASDAQ: STOK) said on Tuesday they are collaborating to develop and ...

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...